Adipex-P

DRUG NAME

• Phentermine hydrochloride [USP]
• Drug Schedule: Schedule 3
• Available As: Tablets and capsules
• Consumption: Swallowed, crushed and injected, crushed and snorted

INDICATION

Commonly prescribed for appetite suppression. Adipex P (Phentermine) is a central nervous system stimulant and sympathomimetic with actions and uses similar to those of DEXTROAMPHETAMINE. It has been used most frequently in the treatment of obesity.

SYNONYMS

Synonyms of Phentermine hydrochloride [USP]

• Adipex-P
• EINECS 214-821-9
• Fastin
• Ionamin
• Lomaira
• MG 18370
• NSC 44090
• Obestin-30
• Oby-Trim
• Ona-Mast
• Ona-Mast hydrochloride
• Phenteral
• Phentermine HCl
• Phentermine hydrochloride
• Phentermyl Wyncaps
• Phenyl-t-butylamine hydrochloride
• S 58
• Suprenza
• Tora
• UNII-0K2I505OTV
• Wilpo (VAN)

INDICATIONS AND USAGE Phentermine hydrochloride is a sympathomimetic amine anorectic indicated as a short-term adjunct (a few weeks) in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index 30 kg/m2, or 27 kg/m2 in the presence of other risk factors (e.g., controlled hypertension, diabetes, hyperlipidemia). (1)

The limited usefulness of agents of this class, including phentermine hydrochloride, should be measured against possible risk factors inherent in their use. (1)

DOSAGE AND ADMINISTRATION

Dosage should be individualized to obtain an adequate response with the lowest effective dose. Late evening administration should be avoided (risk of insomnia). Phentermine hydrochloride can be taken with or without food. Limit the dosage to 15 mg daily for patients with severe renal impairment (eGFR 15 to 29 mL/min/1.73 m2).

DOSAGE FORMS AND STRENGTHS

Tablets containing 37.5 mg phentermine hydrochloride.

CONTRAINDICATIONS

History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) During or within 14 days following the administration of monoamine oxidase inhibitors

• Hyperthyroidism
• Glaucoma
• Agitated states
• History of drug abuse
• Pregnancy
• Nursing
• Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines

WARNINGS AND PRECAUTIONS

Coadministration with other drugs for weight loss is not recommended (safety and efficacy of combination not established). Rare cases of primary pulmonary hypertension have been reported. Phentermine should be discontinued in case of new, unexplained symptoms of dyspnea, angina pectoris, syncope or lower extremity edema. Rare cases of serious regurgitant cardiac valvular disease have been reported.

Tolerance

• Tolerance to the anorectic effect usually develops within a few weeks. If this occurs, phentermine should be discontinued. The recommended dose should not be exceeded.
• Phentermine may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle.
• Risk of abuse and dependence. The least amount feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdosage.
• Concomitant alcohol use may result in an adverse drug reaction.
• Use caution in patients with even mild hypertension (risk of increase in blood pressure).
• A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients.

ADVERSE REACTIONS

Adverse events have been reported in the cardiovascular, central nervous, gastrointestinal, allergic, and endocrine systems.

DRUG INTERACTIONS

• Monoamine oxidase inhibitors: Risk of hypertensive crisis.
• Alcohol: Consider potential interaction
• Insulin and oral hypoglycemics: Requirements may be altered.
• Adrenergic neuron blocking drugs: Hypotensive effect may be decreased by phentermine.

USE IN SPECIFIC POPULATIONS

• Nursing mothers: Discontinue drug or nursing taking into consideration importance of drug to mother.
• Pediatric use: Safety and effectiveness not established.
• Geriatric use: Due to substantial renal excretion, use with caution.
• Renal Impairment: Avoid use in patients with eGFR less than 15 mL/min/m2 or end-stage renal disease requiring dialysis.

CATEGORIES

• Adrenergic Agents
• Anti-Obesity Agents
• Appetite Depressants
• Central Nervous System Agents
• Central Nervous System Stimulants
• Neurotransmitter Agents
• Peripheral Nervous System Agents
• Sympathomimetics

W8MD WEIGHT LOSS CENTERS - PHENTERMINE INFO

• Phentermine information from W8MD weight loss, sleep and medspa centers

Transform Your Life with W8MD Weight Loss Centers

W8MD offers a physician-supervised weight loss program at various locations including New York, Pennsylvania and New Jersey. Our centers provide expert medical guidance, accept most insurances, and offer telemedicine options for convenience.

Why choose W8MD?

• Comprehensive care with FDA-approved medications including:
• Weight loss injections both generic and brand names:
  • Zepbound / Mounjaro, Wegovy / Ozempic, Saxenda
• Weight loss medications including Phentermine, Qsymia, Contrave, Diethylpropion etc.
• Accept most insurances for visits or discounted self pay cost.
• Generic weight loss injections starting from just $125.00 for the starting dose
• In person weight loss NYC and telemedicine medical weight loss options in New York city available

Book Your Appointment

Start your weight loss journey today at our centers in New York, New Jersey and Pennsylvania and visit W8MD.com Call (718)946-5500

• Dailymed label info on Adipex-P
• FDA Adipex-P

Adipex-P Resources
Latest articles Most recent articles Ongoing trials	Wikipedia